Predict Adverse Events by Covid-19 Nephritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04347824|
Recruitment Status : Completed
First Posted : April 15, 2020
Last Update Posted : April 28, 2021
|Condition or disease|
Parameters predicting risks for Covid-19 patients are urgently sought. The current study investigates, if Covid-19 associated nephritis indicating systemic cappillary leak syndrome/severe nephrotic syndrome could be the major driver for complications, predictor for respiratory failure and later need for ICU, and death.
This study intends to generate an algorithm for University hospitals, which allows early detection of Covid-19 associated nephritis and to classify the risk for respiratory decompensation by quantification of severity of nephrotic syndrome.
The rationale of the observational study can be explained by the hypothesis that Covid-19 causes Nephritis: Podocytes express high levels of ACE2, which makes the glomerulus to a target for Covid-19. Other zoonoses, such as Hanta-virus, are a well described cause of nephrotic syndrome inducing cardiopulmonary syndrome. Life-threatening complications of severe nephrotic syndrome are well known as are preventive therapies.
Covid-19 ICU patients with nephritis have
- pulmonary interstitial edema, possibly also due to capillary leak/ nephrotic syndrome;
- immune-incompetence, due to renal loss of immunoglobulins;
- circulatory insufficiency, due to hypalbuminemia (which might explain sudden deaths in the geriatric population);
- less response to some medications caused by impaired plasma protein binding of drugs due to hypalbuminemia and renal loss;
- thromboembolic events, due to antithrombin-deficiency (which might explain lethality in oligo-symptomatic young patients).
In conclusion, ACE2 in the respiratory tract is the gateway for Covid-19 for infection, however, the study postulates that Covid-19 associated nephritis and severe cappillary leak/nephrotic syndrome is a major driver of adverse outcome. If confirmed by others, these findings and algorithm would allow early prediction of later need for ICU-capacity, better allocation of patients for clinical trials, and preventive strategies focused on the nephrotic syndrome including treatment, which can save lives. Same might apply for risk-evaluation of outpatients.
|Study Type :||Observational|
|Actual Enrollment :||223 participants|
|Official Title:||Covid-19 Associated Nephritis as Early Predictor for Complicated Course of Disease|
|Actual Study Start Date :||April 27, 2020|
|Actual Primary Completion Date :||December 31, 2020|
|Actual Study Completion Date :||March 31, 2021|
This group has a normal urine status on admission to hospital. Abnormal urine status is defined anuric OR as 2* or more of the following findings:
This group has an abnormal urine status on admission to hospital WITHOUT serum-albumin below 2.0 g/dl AND WITHOUT antithrombin III level below 70%.
This group has an abnormal urine status on admission to hospital PLUS serum-albumin below 2.0 g/dl OR antithrombin III level below 70%.
- Time to Disease-Aggravation [ Time Frame: during first 10 days after admission to hospital ]Time (in days) from hospital admission to transferral to ICU (ICU level high) OR time (in days) from Hospital Admission to Death
- Complications [ Time Frame: during first 10 days after admission to hospital ]
Number of Complications are defined as
- Need of transferral to "ICU low" (ICU level 1)*
- Need of transferral to "ICU high" (ICU level 3)*
- Need of mechanical ventilation* OR
- Need for renal replacement therapy* OR
- Need of extracorporeal membrane oxygenation* OR
- Death * in the first 10 days after admission to hospital
- Resources [ Time Frame: during hospital stay, up to 2 months ]
- Time on "ICU low" (in days),
- Time on "ICU high" (in days),
- Time on invasive mechanical ventilation (in days)
- Time on extracorporeal membrane oxygenation (in days)
- Time on renal replacement therapy (in days)
- Blood-test [ Time Frame: during hospital stay, up to 2 months ]
- lowest serum-albumin
- lowest antithrombin III
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04347824
|University Medical Center Goettingen|